Ahlcon Parenterals (India) Ltd Stock Analysis

BSE: 524448 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Ahlcon Parenteral (I

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

2. Valuation


3. Price Trend


1. Is Ahlcon Parenterals (India) Ltd. a good quality company?

Data is not available for this company.

2. Is Ahlcon Parenterals (India) Ltd. undervalued or overvalued?

No data found

3. Is Ahlcon Parenterals (India) Ltd. a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Ahlcon Parenterals (India) Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Ahlcon Parenteral (I:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide
ROCE % 11.3%11.5%21.5%21.8%8.8%-0.7%1.1%-8.1%-10%1.7%-
Value Creation Index -0.2-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 62.479.7108120116119135150156174174
YoY Gr. Rt. %-27.7%35.1%11.4%-3.3%2.6%13.8%10.5%4%12.1%-
Adj EPS 6.16.617.727.124.6-19.2-11.8-62.6-67.1-20.8-21.7
YoY Gr. Rt. %-9.2%166.4%53.3%-9.2%-178.1%NANANANA-
BVPS (₹) 51.757.475.1102.1124.89979.819.5-46.6-68.2119.5
Adj Net Profit 4.44.812.719.517.7-13.8-8.5-45-48.3-15-16
Cash Flow from Ops. 38.59.317.131.27.812.734.738.730.3-
Debt/CF from Ops.


CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales 12.1%8.5%8.8%12.1%
Adj EPS -214.7%-196.7%NANA
BVPS -203.1-188.6-194.90
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide
Return on Equity % 11.911.926.230.421.7-17.2-13.1-126496.336.2-84.4
Op. Profit Mgn % 18.216.822.928.723.112.619.812.87.718.925.6
Net Profit Mgn % 7611.816.315.3-11.6-6.3-30.1-31.1-8.6-8.9
Debt to Equity
Working Cap Days 1251231071221491521401411531430
Cash Conv. Cycle 64605567861031019083760

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Ahlcon Parenterals (India) Ltd.

Standalone Consolidated
TTM EPS (₹) -21.7 -
TTM Sales (₹ Cr.) 174 -
BVPS (₹.) 119.5 -
Reserves (₹ Cr.) 79 -
P/BV 4.31 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 514.75 / 517.25
All Time Low / High (₹) 2.00 / 598.00
Market Cap (₹ Cr.) 371
Equity (₹ Cr.) 7.2
Face Value (₹) 10
Industry PE 40.3

Management X-Ray of Ahlcon Parenteral (I :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes


About Ahlcon Parenterals (India) Ltd

Ahlcon Parenterals (India), incorporated in 1992, is engaged in manufacturing life saving Intravenous fluids and medical disposals by employing a highly sophisticated production process, the aseptic form-fill-seal technology imported from Switzerland.

Ahlcon has an installed capacity of 30 million bottles per annum for LVP in pack size of 100ml and 500ml. Further, 200ml and 300ml packs are being launched in near future.

The company also has capacity of 60 million vials of eye drops and injections in the fill size of 2ml, 3ml, 5ml & 10ml both in transparent and white opaque packs as SVP.

Within a short span of time since its inception, the company has achieved the quality certification from WHO-GMP International and ISO 9002, a landmark achievement which ensures international quality standards with ultimate objective of getting the MCA approval.


Antimicrobial I V fluids, eye and ear drops, ointments, other products such as respiratory solutions, plasma volume expander and many more.

Read More Read Less